BackZyVersa Therapeutics Overview

ZyVersa Therapeutics Other Current Assets

Latest other current assets for ZVSA: $440M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$439.56M
↓ 11.87% YoYΔ $-59.22M vs prior year quarter

Peer average / median

Loading

ZyVersa Therapeutics Other Current Assets History

Loading

ZyVersa Therapeutics vs. peers: Other Current Assets Comparison

Loading

ZyVersa Therapeutics Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ZyVersa Therapeutics (ZVSA) FAQ

As of the most recent data (March 2026), ZVSA shows a other current assets of $440M. That compares with $500M in the prior-year period — down 11.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZVSA's other current assets is now $440M (was $500M) — a 11.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ZyVersa Therapeutics is outperforming or lagging.

Tracking ZVSA's other current assets over time shows whether ZyVersa Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $440M That compares with $500M in the prior-year period — down 11.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has ZyVersa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $440M) with ownership activity and broader fundamentals.